A Phase I/II Trial of Rituxan and BEAM High-Dose Chemotherapy and Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma
Objectives: I. To determine the response rate, complete and partial, of patients with
indolent lymphoma receiving Rituxan and BEAM with autologous stem cell transplant. II. To
determine if the addition of Rituxan changes the toxicity profile attributed to high-dose
BEAM chemotherapy.
This protocol is a phase I/II trial combining the Rituxan as a pre and post-transplant agent
to aid in the chemotherapy sensitization and the treatment of minimal residual disease
post-transplant.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
response rate
100 day
No
Julie M Vose, M.D.
Principal Investigator
University of Nebraska
United States: Institutional Review Board
138-98
NCT00572013
May 1998
September 2009
Name | Location |
---|---|
University of Nebraska Medical Center, Section of Oncology/Hematology | Omaha, Nebraska 68198-7680 |